Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. OncoCyte's shares outstanding for the quarter that ended in Sep. 2022 was 118.62 Mil.
OncoCyte's quarterly shares outstanding
increased
from Jun. 2022 (118.61 Mil) to Sep. 2022 (118.62 Mil).
It means OncoCyte issued new shares from Jun. 2022 to Sep. 2022 .
OncoCyte's annual shares outstanding
increased
from Dec. 2020 (69.12 Mil) to Dec. 2021 (92.23 Mil).
It means OncoCyte issued new shares from Dec. 2020 to Dec. 2021 .
OncoCyte Shares Outstanding (EOP) Historical Data
The historical data trend for OncoCyte's Shares Outstanding (EOP) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
OncoCyte Annual Data
Trend
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Shares Outstanding (EOP)
31.45
40.66
57.03
69.12
92.23
OncoCyte Quarterly Data
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Shares Outstanding (EOP)
92.16
92.23
92.25
118.61
118.62
Competitive Comparison
For the Biotechnology subindustry, OncoCyte's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OncoCyte Shares Outstanding (EOP) Distribution
For the Biotechnology industry and Healthcare sector, OncoCyte's Shares Outstanding (EOP) distribution charts can be found below:
* The bar in red indicates where OncoCyte's Shares Outstanding (EOP) falls in comparison to its industry or sector. The grey bar indicates the Shares Outstanding (EOP)'s extreme value range as defined by GuruFocus.
OncoCyte Shares Outstanding (EOP) Calculation
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
OncoCyte Shares Outstanding (EOP) Related Terms
Thank you for viewing the detailed overview of OncoCyte's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States, and it earns revenue from the sale of diagnostic tests.
Create New Portfolio
Portfolio Contest
Personalize
Premium Gurus 
0.01(3.94%) Volume: 286,154 12:56PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
OCX has been successfully added to your 
